by Biospring | Aug 1, 2022 | Advanced Therapy, Biologics, Biomanufacturing, CDMO, Cell and Gene Therapy, CGT, Drug Development, Life Sciences Technology
For a biotech company, discovering a new therapeutic candidate is a years-long, herculean achievement. A crucial question post-discovery is, can the drug be manufactured at scale? Companies must ensure that they can procure enough of a new therapy for clinical trials...
by Biospring | Apr 25, 2022 | Abzena, Biologics, Biotech, CDMO, COVID-19, Drug Development, Drug Discovery, Drug Manufacturing, Pharma, Sven Lee
We shared an overview on Abzena following our investment in July. Over the past few months, Abzena has launched a new facility in San Diego and has made several executive hires. We recently spoke with Sven Lee, Chief Business Officer at Abzena, and he provided us with...
by Biospring | Apr 24, 2022 | Abzena, Biologics, Biotech, CDMO, Drug Development, Pharma
Over the past few months, the COVID-19 pandemic has revealed gaps in the global pharmaceutical supply chain for drugs in clinical trials and for marketed drugs. Drug manufacturing can be a long and complex process requiring specialized expertise. The biopharmaceutical...
